| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hui-Ling Wang, Yu-Tao Xiang, Qiu-Ying Li, Xiao-Ping Wang, Zhong-Chun Liu, Shi-Sheng Hao, Xuan Liu, Lin-Lin Liu, Gao-Hua Wang, De-Gang Wang, Ping-An Zhang, An-Yu Bao, Helen F K Chiu, Gabor S Ungvari, Kelly Y C Lai, Robert W Buchana. The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii. Journal of psychiatric research. vol 53. 2014-11-24. PMID:24656425. |
the artemether-risperidone combination is safe and well tolerated, but artemether as an adjunct to risperidone does not appear to alleviate cognitive deficits of schizophrenia. |
2014-11-24 |
2023-08-12 |
human |
| J Tian, W Wang, L Ye, X Cen, X Guan, J Zhang, P Yu, G Du, W Liu, Y L. A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs. Human & experimental toxicology. vol 33. issue 5. 2014-11-18. PMID:23925946. |
risperidone, a 5-ht2 and dopaminergic d2 receptor antagonist, was developed as long-acting sustained-release microspheres with poly(lactide-co-glycolide) (plga) as a drug carrier for the treatment of schizophrenia. |
2014-11-18 |
2023-08-12 |
Not clear |
| Almari Ginory, Mathew Nguye. A case of priapism with risperidone. Case reports in psychiatry. vol 2014. 2014-11-07. PMID:25379316. |
this is case of a 50-year-old male with a history of schizophrenia with previous priapism related to trazodone, who presents with new onset priapism associated with risperidone. |
2014-11-07 |
2023-08-13 |
Not clear |
| Nathan L Hutcheson, David G Clark, Mark S Bolding, David M White, Adrienne C Laht. Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry research. vol 221. issue 1. 2014-11-05. PMID:24210948. |
we investigated the relationship between basal ganglia volume and treatment response to the atypical antipsychotic medication risperidone in unmedicated patients with schizophrenia. |
2014-11-05 |
2023-08-12 |
human |
| Simon Frey, Roland Linder, Georg Juckel, Tom Stargard. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. The European journal of health economics : HEPAC : health economics in prevention and care. vol 15. issue 2. 2014-10-27. PMID:23420082. |
cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a markov model parameterized using administrative data. |
2014-10-27 |
2023-08-12 |
Not clear |
| Simon Frey, Roland Linder, Georg Juckel, Tom Stargard. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. The European journal of health economics : HEPAC : health economics in prevention and care. vol 15. issue 2. 2014-10-27. PMID:23420082. |
we use longitudinal patient-level data from a german sickness fund with 7.26 million insured in a markov-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (lai-ris) compared with long-acting injectable flupentixol (lai-flx) in the long-term management of schizophrenia. |
2014-10-27 |
2023-08-12 |
Not clear |
| Arash Mirabzadeh, Pooneh Kimiaghalam, Farbod Fadai, Mercedeh Samiei, Reza Daneshman. The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. Basic and clinical neuroscience. vol 5. issue 3. 2014-10-22. PMID:25337382. |
the therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. |
2014-10-22 |
2023-08-13 |
Not clear |
| Arash Mirabzadeh, Pooneh Kimiaghalam, Farbod Fadai, Mercedeh Samiei, Reza Daneshman. The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. Basic and clinical neuroscience. vol 5. issue 3. 2014-10-22. PMID:25337382. |
the present study examined the therapeutic effectiveness of manufactured risperidone and haloperidol in iran on treating the negative symptoms of schizophrenia. |
2014-10-22 |
2023-08-13 |
Not clear |
| Hong-Xia Zhang, Xiao-Ling Shen, Hui Zhou, Xiao-Min Yang, Hui-Fang Wang, Kai-Da Jian. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai. Psychiatry research. vol 215. issue 1. 2014-10-17. PMID:24230993. |
398 drug-naïve patients met the criteria of schizophrenia using icd-10 criteria were recruited from shanghai mental health center and treated with one of three second generation antipsychotics (risperidone, olanzapine or quetiapine). |
2014-10-17 |
2023-08-12 |
Not clear |
| H Kimura, Nobuhisa Kanahara, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Masayuki Yoshimura, H Yamanaka, Tomotada Suzuki, Hideki Komatsu, Y Sekine, Hiroyuki Watanabe, Masaomi Iy. [Effectiveness of long-acting injectable risperidone for patients with treatment refractory schizophrenia]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 33. issue 2. 2014-10-16. PMID:25314746. |
[effectiveness of long-acting injectable risperidone for patients with treatment refractory schizophrenia]. |
2014-10-16 |
2023-08-13 |
Not clear |
| Vincent Dubois, Joseph Peuskens, Paul Geerts, Johan Detrau. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early intervention in psychiatry. vol 8. issue 1. 2014-10-10. PMID:23343330. |
clinical outcomes of long-acting risperidone in recent versus long-term diagnosed belgian schizophrenic patients: results from electronic schizophrenia treatment adherence registry (e-star) and trial for the initiation and maintenance of remission in schizophrenia with risperidone (timores). |
2014-10-10 |
2023-08-12 |
Not clear |
| Vincent Dubois, Joseph Peuskens, Paul Geerts, Johan Detrau. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early intervention in psychiatry. vol 8. issue 1. 2014-10-10. PMID:23343330. |
potential differences in psychiatric clinical outcomes and hospitalization rates before and after the initiation of long-acting risperidone among recently and long-term diagnosed schizophrenia patients were studied. |
2014-10-10 |
2023-08-12 |
Not clear |
| Jennifer A Hadley, Rodolphe Nenert, Nina V Kraguljac, Mark S Bolding, David M White, Frank M Skidmore, Kristina M Visscher, Adrienne C Laht. Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 4. 2014-10-10. PMID:24165885. |
using resting-state functional mri, we examined the functional connectivity of the ventral tegmental area (vta), the origin of the mesocorticolimbic dopamine projections, in 21 healthy controls and 21 unmedicated patients with schizophrenia at baseline (pre-treatment) and after 1 week of treatment with the antipsychotic drug risperidone (1-week post-treatment). |
2014-10-10 |
2023-08-12 |
Not clear |
| R Grohmann, R R Engel, H-J Möller, E Rüther, J W van der Velden, S Stübne. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. European archives of psychiatry and clinical neuroscience. vol 264. issue 2. 2014-10-09. PMID:23835526. |
type and frequency of severe adrs attributed to flupentixol were compared with haloperidol, clozapine, olanzapine, quetiapine, risperidone and amisulpride in a total of 56,861 schizophrenia inpatients exposed to these drugs. |
2014-10-09 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Gen, Yuichi Inoue, Hiroyuki Hibino, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikam. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. International journal of psychiatry in clinical practice. vol 18. issue 1. 2014-10-06. PMID:24047427. |
the influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. |
2014-10-06 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Gen, Yuichi Inoue, Hiroyuki Hibino, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikam. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. International journal of psychiatry in clinical practice. vol 18. issue 1. 2014-10-06. PMID:24047427. |
this study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (pal). |
2014-10-06 |
2023-08-12 |
Not clear |
| Saeed Shoja Shafti, Mahsa Gilanipoo. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia. Schizophrenia research and treatment. vol 2014. 2014-09-23. PMID:25247096. |
a comparative study between olanzapine and risperidone in the management of schizophrenia. |
2014-09-23 |
2023-08-13 |
Not clear |
| Hung-Yu Chan, An-Sheng Lin, Kun-Po Chen, Jror-Serk Cheng, Ying-Yeh Chen, Chang-Jer Tsa. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. Journal of clinical psychopharmacology. vol 33. issue 6. 2014-09-15. PMID:24100785. |
thirty-nine patients with schizophrenia (diagnostic and statistical manual of mental disorders, fourth edition) who met the criteria of a positive and negative syndrome scale (panss) total score of greater than or equal to 60 points, panss-excitement component (ec) score of greater than or equal to 14 points, and at least 1 panss-ec score of greater than or equal to 4 were randomly assigned to either the zotepine or risperidone group. |
2014-09-15 |
2023-08-12 |
Not clear |
| Sebastian Walther, Franz Moggi, Helge Horn, Konstantin Moskvitin, Christoph Abderhalden, Nadja Maier, Werner Strik, Thomas J Mülle. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. Journal of clinical psychopharmacology. vol 34. issue 1. 2014-08-29. PMID:24346752. |
we aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with schizophrenia or schizophreniform or schizoaffective disorder over 96 hours using a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen. |
2014-08-29 |
2023-08-12 |
Not clear |
| b' Zofia Rog\\xc3\\xb3\\xc5\\xb. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacological reports : PR. vol 65. issue 5. 2014-08-25. PMID:24399737.' |
several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve treatment of the negative and certain cognitive symptoms of schizophrenia. |
2014-08-25 |
2023-08-12 |
mouse |